Prodromal Alzheimer’s disease – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 18 Jun 2026 04:08:01 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Prodromal Alzheimer’s disease – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Using [18F]DED PET imaging to study brain changes in patients with Alzheimer’s disease, CADASIL, and other forms of dementia. https://clinicaltrials.eu/trial/using-18f-ded-pet-imaging-to-study-brain-changes-in-patients-with-alzheimer-s-disease-cadasil-and-other-forms-of-dementia/ Wed, 29 Apr 2026 15:09:38 +0000 https://clinicaltrials.eu/trial/using-18f-ded-pet-imaging-to-study-brain-changes-in-patients-with-alzheimer-s-disease-cadasil-and-other-forms-of-dementia/ This study focuses on understanding brain changes in people living with various forms of Dementia, which is a group of symptoms that affect memory, thinking, and social abilities. The research includes specific types of the condition such as Alzheimer’s Disease, including cases that are Autosomal Dominant Alzheimer’s Disease, Late onset Alzheimer Disease, and Sporadic early onset Alzheimer Disease. Additionally, the study involves individuals with CADASIL, a rare genetic condition that affects the small blood vessels in the brain. The primary goal is to investigate how certain brain cells called astrocytes react during the progression of these diseases.

To observe these changes, a specialized imaging technique called PET, or positron emission tomography, will be used. During the process, a substance known as [18F]DED will be administered through an intravenous injection, which means it is delivered directly into a vein. This substance acts as a tracer that allows doctors to see specific activities in the brain through medical scans. This imaging process helps to identify how the brain cells are behaving in different stages of neurodegenerative diseases, which are conditions where the nervous system gradually declines over time.

]]> Study on the Accuracy of Tau PET ([18F]RO6958948) and Vizamyl (Flutemetamol 18F) in Diagnosing Mild Cognitive Symptoms and Risk of Alzheimer’s Disease https://clinicaltrials.eu/trial/study-on-the-accuracy-of-tau-pet-18fro6958948-and-vizamyl-flutemetamol-18f-in-diagnosing-mild-cognitive-symptoms-and-risk-of-alzheimers-disease/ Wed, 29 Apr 2026 15:05:45 +0000 https://clinicaltrials.eu/trial/study-on-the-accuracy-of-tau-pet-18fro6958948-and-vizamyl-flutemetamol-18f-in-diagnosing-mild-cognitive-symptoms-and-risk-of-alzheimers-disease/ The study focuses on understanding and improving the diagnosis of certain brain disorders known as neurodegenerative disorders. These include conditions like Alzheimer’s disease, progressive supranuclear palsy, frontotemporal dementia, corticobasal degeneration, and mild cognitive impairment. The study uses two special substances, Vizamyl and [18F]RO6958948, which are injected into the body to help doctors see changes in the brain using a type of scan called PET (Positron Emission Tomography).

The purpose of the study is to see how well these substances can help identify people who are at risk of developing dementia, a condition that affects memory and thinking. Participants in the study will receive an injection of either Vizamyl or [18F]RO6958948. These substances help highlight areas in the brain that may be affected by the disorders. The study will compare the brain scans of people with these disorders to those of healthy individuals to better understand the differences.

Throughout the study, participants will undergo various tests, including brain scans and cognitive assessments, to monitor their brain health and cognitive function. The study aims to gather information over time to see how these disorders progress and how the substances used in the study can aid in early detection and diagnosis. This research hopes to provide valuable insights into the early stages of these disorders and improve the way they are diagnosed and understood.

]]> Study of RO7269162 in people at risk for or with early-stage Alzheimer’s Disease: Effects on brain amyloid buildup https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-ro7269162-for-patients-at-risk-or-in-early-stages-of-alzheimers-disease/ Wed, 29 Apr 2026 14:47:53 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-ro7269162-for-patients-at-risk-or-in-early-stages-of-alzheimers-disease/ This study focuses on people who are at risk for or in the early stages of Alzheimer’s Disease, a brain condition that affects memory and thinking abilities. The research will test a new medication called RO7269162, which is taken as oral capsules, comparing it with a placebo to understand how well it works and how safe it is. The study aims to examine how this medication affects various markers of brain health, particularly the buildup of amyloid, a protein associated with Alzheimer’s Disease.

During the study, participants will receive either RO7269162 or placebo capsules to take daily for up to 72 weeks. To monitor brain changes, participants will undergo PET scans using special imaging substances called florbetaben or flutemetamol, which are given through slow injection into a vein. These substances help make brain amyloid visible during the scanning procedure.

Throughout the study, various health measurements will be taken to ensure participant safety and to understand how the medication affects the body. This includes monitoring vital signs, conducting medical tests, and collecting samples to measure the levels of different substances in the blood and spinal fluid that are related to Alzheimer’s Disease.

]]> Study of Lecanemab (BAN2401) Treatment in People with Early Alzheimer’s Disease: Testing Safety and Effectiveness Over 18 Months https://clinicaltrials.eu/trial/study-on-the-effects-of-lecanemab-in-patients-with-early-alzheimers-disease/ Wed, 29 Apr 2026 14:27:07 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-lecanemab-in-patients-with-early-alzheimers-disease/ This study focuses on testing a medication called lecanemab (also known as BAN2401) in people with Early Alzheimer’s Disease. This condition includes both mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s disease dementia, which causes gradual memory decline and difficulties with daily activities. The purpose is to determine if the medication can help slow down the progression of early-stage Alzheimer’s disease symptoms.

The study medication lecanemab is given through intravenous infusion, which means it is delivered directly into the bloodstream through a vein. Some participants will receive the actual medication while others will receive a placebo. The study consists of two parts: an 18-month main phase followed by an extension phase where all participants can receive the actual medication.

During the study, participants will receive regular infusions of either lecanemab or placebo. The maximum dose used in the study is 10 milligrams per kilogram of body weight. Participants will need to have a study partner who spends at least 8 hours per week with them to help monitor their condition throughout the study. The total duration of treatment may last up to 48 months, including both the main phase and extension phase of the study.

]]>